VERDESO Foam is a white to off-white petrolatum-based emulsion aerosol foam containing the active ingredient desonide, a low-potency topical corticosteroid.
VERDESO® (desonide) Foam, 0.05% is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.
Patients should be instructed to use VERDESO Foam for the minimum amount of time necessary to achieve the desired results because of the potential for VERDESO Foam to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Treatment should not exceed 4 consecutive weeks.
Published Studies Related to Verdeso (Desonide Topical)
An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. [2009.11]
The treatment of seborrheic dermatitis includes topical antifungal agents to eradicate Malassezia spp, corticosteroids, which treat the inflammatory component of the disease and keratolytics which remove scale and crust. This study compared the efficacy of a nonsteroidal topical cream and a low-potency topical corticosteroid for the treatment of mild to moderate seborrheic dermatitis of the face in 77 volunteers randomized to twice-daily treatment with nonsteroidal cream or corticosteroid cream for up to 28 days...
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. [2007.02]
Low to mid potency corticosteroids remain a cornerstone of therapy for atopic dermatitis (AD)...
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. [2005.03]
CONCLUSION: The presence of 0.05% desonide does not impair or improve the Malassezia susceptibility to 2% ketoconazole when growing on lipid-enriched human stratum corneum. Copyright 2005 S. Karger AG, Basel.
Overview on desonide 0.05%: a clinical safety profile. [2004.07]
Desonide (as a cream, ointment, or lotion formulation) is widely used for the treatment of steroid-responsive dermatoses... The excellent safety profile of desonide revealed by this pharmacovigilance program is supported by a review of published clinical trial results.
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. [2002.08]
The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild- to mid-potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis...
Clinical Trials Related to Verdeso (Desonide Topical)
Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis [Recruiting]
The purpose of this study is to compare the effects of an amino acid moisturizing cream and
desonide cream in reducing skin symptoms associated with AD/eczema in subjects with mild to
moderate atopic dermatitis/eczema.
Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation [Completed]
Axillary hyperpigmentation is a frequent consultation in dark skin populations although its
exact prevalency is unknown. Currently, there are not studies about physiopathology and
treatment for this entity. The objective is to evaluate the depigmenting effect of topical
4% niacinamide versus 0. 05% desonide in axillary hyperpigmentation.
At least 30 axillas with hyperpigmentation in individuals of phototype III-V, aged 18-50
years are going to be randomly assigned to receive niacinamide, desonide or placebo daily.
No hygienic habits will not be modified. Volunteers will be evaluated at baseline and for 9
weeks, by means of histological, histochemical and immunohistochemistry analysis, as well as
Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis [Completed]
The purpose of this research study is to better understand how this study drug works when
people use it to treat atopic dermatitis. Desonate has been approved by the US Food and
Drug Administration (FDA) for atopic dermatitis.
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis [Completed]
This study compares the effectiveness of two topical creams for atopic dermatitis in
pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice
daily for 6 weeks or until clear.
Emollients in the Management of Atopic Dermatitis [Completed]
The purpose of this study is to confirm that emollients play a major role in the maintenance
therapy after clearing of inflammatory lesions and can reduce occurrence of flares in
children with atopic dermatitis.